To analyze the efficacy of levocarnitine combined with benazepril for patients with essential hypertension(EH) and heart failure(HF), and its effects on exercise endurance and cardiovascular protection.
A total of 160 patients with EH and HF treated in our hospital from January 2022 to December 2024 were included.They were divided into the observation group and the control group by simple random sorting method, with 80 cases in each group. All patients received conventional treatment, and the control group was treated with benazepril, while the observation group was treated with levocarnitine as an adjunct to benazepril. The clinical efficacy, exercise endurance, cardiac function indicators, blood pressure, cardiovascular events, and safety were compared between the two groups.
After treatment, the total clinical effective rate of the observation group was higher than that of the control group(78.75% vs. 63.75%, P<0.05). After treatment, the peak oxygen consumption, maximum exercise duration, and six-minute walking test distance in both groups improved compared to pre-treatment(P<0.05), and the observation group was higher than the control group(P<0.05. After treatment, the left ventricular ejection fraction in both groups increased compared to pre-treatment(P<0.05), and the observation group was higher than the control group(P<0.05), the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and heart rate in both groups decreased compared to pre-treatment(P<0.05), and the observation group was lower than the control group(P<0.05). After treatment, the diastolic and systolic blood pressures in both groups decreased compared to pre-treatment(P<0.05), and the observation group was lower than the control group(P<0.05). During treatment, the total incidence of cardiovascular events in the observation group was lower than that in the control group(7.50% vs. 18.75%, P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups during treatment(P>0.05).
Levocarnitine combined with benazepril is effective in treating EH with HF, and can further improve the exercise endurance and cardiac function of patients and protect the cardiovascular system.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |